高瓴资本超级重仓!绝对是最被低估的创新药龙头,甚至没有之一!

萝卜投研
Jul 04, 2025

金斯瑞科技最近迎来大利好!6月30日,金斯瑞生物科技公告称,截至2025年6月27日,其控股子公司南京蓬勃及镇江蓬勃(统称“蓬勃生物”)已根据与礼新医药签署的经重述及修订的许可协议,累计获得约2.138亿美元(税后)的付款。该笔巨额资金包括首付款、首个里程碑付款,以及与抗PD-1单域抗体相关的分许可收入。值得注意的是,该抗体正是礼新医药开发的PD-1/VEGF双抗LM-299的关键组成部分。公司...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10